Swaminathan Padmanabhan Iyer

From the 2026 National Summit on Hematologic Cancers

Supplementary Figure S5: Comparison of copy number alteration frequencies between post-CART19 and CART19-naïve models. Statistical comparison of the frequency of DNA copy number alterations between post-CAR T and CAR-naïve PDX models. Lesions correspond to GISTIC peaks shown in Supplementary Figure S1. *Fisher exact P < 0.05.

Molecular characteristics of 48 cases LBCL PDX from MD Anderson.

Differentially expressed genes between CD19-positive and CD19-negative PDX.

Supplementary Figure S4: Immunohistochemical staining of the murine macrophage marker F4/80. IHC corresponding to Figure 5D showing zoomed out images of H&E, CD4 IHC and CD8 IHC, together with IHC staining for the myeloid marker F4/80.

Supplementary Figure S2: Lollipop plot of MYD88 and CD79B mutations from PDX models. Plots show the frequency of protein coding mutations in MYD88 (above) and CD79B (below), including hotspots at L252 and Y196, respectively. The cell of origin (purple, ABC; yellow, GCB) and LymphGen subtype for cases with MYD88 and/or CD79B mutations are summarized on the right.

Clinical features of 48 cases LBCL PDX from MD Anderson.

Supplementary Figure S3: Gating hierarchy for Figure 5A. Cells shown in Figure 5A have been gated on intact single cells by forward scatter, side scatter and autofluorescence, and viable cells using viability dye.

Differentially expressed genes between post-CART19 and CART19-naïve models.

Supplementary Figure S6: Flow cytometry gating hierarchy for Figure 7B. Cells shown in figure 7B are gated on viable lymphocytes and singlets by forward and side scatter.